NCT05794165
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
Enrolling by Invitation
PHASE2Ages 18+InterventionalTreatmentBryan CottonInvestigator-initiated
~314 participants
Updated 2025-05-14 on ClinicalTrials.gov
What's tested:Thrombate infusionPlacebo
At a glance
Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with incidences of venous thromboembolism (VTE )
Measured over 14 days post hospital admission
+1 more outcome measured
Conditions
Where it's being run
4 sites across 4 statesColorado1
Florida1
Tennessee1
Texas1
Study leadership
- Bryan A Cotton, MD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Admission to trauma service
Polytraumatic injuries OR pelvic/long bone fracture
Planned admission to trauma ICU or step-down/SIMU setting (this includes STICU, SIMU/TIMU, BICU, and BIMU)
Informed consent obtained
Exclusion
Prisoners (defined as those directly admitted from correctional facility)
Known or suspected pregnancy
≥ 20% total body surface area (TBSA) burned
Nonsurvivable head injuries
Known hematologic or immunologic disorders
Known prehospital anticoagulant use
Patients initially placed on unfractionated heparin for thromboprophylaxis
Known allergy to Antithrombin or it's components
Enrollment in another interventional study unless approved by Trial Principal Investigator
What this trial measures
- Number of participants with incidences of venous thromboembolism (VTE )14 days post hospital admission
- Number of participants with incidence of antifactor Xa (anti-FXa) of ≥0.2 IU/mL14 days post hospital admission